Поиск
Закладки
Озвучить текст Озвучить книгу
Изменить режим чтения
Изменить размер шрифта
Оглавление
Для озвучивания и цитирования книги перейдите в режим постраничного просмотра.
Гемофилия

Список литературы

  1. Воробьев А.И. et al. Протокол ведения больных “Гемофилия” // Проблемы стандартизации в здравоохранении. 2006. Vol. 3. P. 18–74.
  2. Teitel J. et al. Canadian Hemophilia Standards Group. Canadian Comprehensive Care Standards for Hemophilia and Other Inherited Bleeding Disorders, First Edition. 2007. P. 32.
  3. Srivastava A. et al. Guidelines for the management of hemophilia // Haemophilia. John Wiley & Sons, Ltd, 2013. Vol. 19, № 1. P. e1–e47.
  4. Astermark J. et al. Primary prophylaxis in severe haemophilia should be started at an early age but can be individualized // Br. J. Haematol. Br J Haematol, 1999. Vol. 105, № 4. P. 1109–1113.
  5. Oldenburg J. et al. Emicizumab prophylaxis in hemophilia A with inhibitors // N. Engl. J. Med. Massachussetts Medical Society, 2017. Vol. 377, № 9. P. 809–818.
  6. Момот А.П. Патология гемостаза. Принципы и алгоритмы клинико-лабораторной диагностики. СПб: ФормаТ, 2008. 208 p.
  7. Gouw S.C. et al. F8 gene mutation type and inhibitor development in patients with severe hemophilia A: Systematic review and meta-analysis // Blood. Blood, 2012. Vol. 119, № 12. P. 2922–2934.
  8. Miller C.H. Laboratory testing for factor VIII and IX inhibitors in haemophilia: A review // Haemophilia. Blackwell Publishing Ltd, 2018. Vol. 24, № 2. P. 186–197.
  9. Зозуля Н.И. Диагностика и лечение ингибиторной формы гемофилии. Автореферат на соискание ученой степени доктора медицинских наук. 2010. P. 41.
  10. Collins P.W. et al. Diagnosis and treatment of factor VIII and IX inhibitors in congenital haemophilia: (4th edition) // Br. J. Haematol. 2013. Vol. 160, № 2. P. 153–170.
  11. De Moerloose P. et al. Recommendations for assessment, monitoring and follow-up of patients with haemophilia // Haemophilia. Haemophilia, 2012. Vol. 18, № 3. P. 319–325.
  12. Osooli M., Berntorp E. Inhibitors in haemophilia: what have we learned from registries? A systematic review // J. Intern. Med. J Intern Med, 2015. Vol. 277, № 1. P. 1–15.
  13. Male C. et al. Inhibitor incidence in an unselected cohort of previously untreated patients with severe haemophilia B: a PedNet study // Haematologica. Haematologica, 2021. Vol. 106, № 1. P. 123–129.
  14. Nogami K. The utility of thromboelastography in inherited and acquired bleeding disorders // Br. J. Haematol. John Wiley & Sons, Ltd, 2016. Vol. 174, № 4. P. 503–514.
  15. Pickles C.W., Biss T., Bitar R. Gastrointestinal Bleeding in Children With Hemophilia A: // https://doi.org/10.1177/0009922817732150. SAGE PublicationsSage CA: Los Angeles, CA, 2017. Vol. 57, № 7. P. 854–856.
  16. Park N., Jang J.S., Cha J.H. Acquired Hemophilia A with Gastrointestinal Bleeding // Clin. Endosc. Korean Society of Gastrointestinal Endoscopy, 2020. Vol. 53, № 1. P. 90.
  17. QUON D. V., KONKLE B.A. How we treat: Haematuria in adults with haemophilia // Haemophilia. John Wiley & Sons, Ltd, 2010. Vol. 16, № 4. P. 683–685.
  18. Wojtyś M. et al. Acquired hemophilia A as a cause of recurrent bleeding into the pleural cavity – case report and literature review // Kardiochirurgia i Torakochirurgia Pol. = Polish J. Cardio-Thoracic Surg. Termedia Publishing, 2014. Vol. 11, № 3. P. 329.
  19. Kasai H. et al. Repeated Diffuse Alveolar Hemorrhage in a Patient with Hemophilia B // Intern. Med. Japanese Society of Internal Medicine, 2017. Vol. 56, № 4. P. 425.
  20. Golestani M. et al. Comparison of bypassing agents in bleeding reduction in treatment of bleeding episodes in patients with haemophilia and inhibitors // Iranian Red Crescent Medical Journal. Kowsar Medical Publishing Company, 2014. Vol. 16, № 12. P. 24551.
  21. Mannucci P.M., Garagiola I. Factor VIII products in haemophilia A: One size fits all? // Thromb. Haemost. Schattauer GmbH, 2015. Vol. 113, № 5. P. 911–914.
  22. Colvin B.T. et al. European principles of haemophilia care // Haemophilia. Haemophilia, 2008. Vol. 14, № 2. P. 361–374.
  23. Richards M. et al. A United Kingdom haemophilia centre doctors’ organization guideline approved by the British committee for standards in haematology: Guideline on the use of prophylactic factor VIII concentrate in children and adults with severe haemophilia A // British Journal of Haematology. Br J Haematol, 2010. Vol. 149, № 4. P. 498–507.
  24. Румянцев А.Г., Румянцев С.А., Чернов В.М. Гемофилия в практике врачей различных специальностей. ГЭОТАР-Медицина, 2012. 132 p.
  25. Mahlangu J. et al. Defining extended half-life rFVIII-A critical review of the evidence // Haemophilia. Haemophilia, 2018. Vol. 24, № 3. P. 348–358.
  26. Santagostino E. et al. Safety and pharmacokinetics of a novel recombinant fusion protein linking coagulation factor IX with albumin (rIX-FP) in hemophilia B patients // Blood. Blood, 2012. Vol. 120, № 12. P. 2405–2411.
  27. NILSSON I.M. et al. Twenty‐five years’ experience of prophylactic treatment in severe haemophilia A and B // J. Intern. Med. J Intern Med, 1992. Vol. 232, № 1. P. 25–32.
  28. Инструкция по медицинскому применению лекарственного препарата Афстила®, ЛП-006975, дата регистрации 26.04.2021.
  29. Инструкция по медицинскому применению препарата Элоктейт (эфмороктоког альфа), ЛП-006034.
  30. Инструкция по медицинскому применению лекарственного препарата Аденовейт. РУ ЛП 007238 от 30.07.21.
  31. Инструкция по медицинскому применению лекарственного препарата Идельвион®, ЛП-007569, дата регистрации 01.11.2021.
  32. Monahan P.E. et al. Safety and efficacy of investigator-prescribed BeneFIX prophylaxis in children less than 6 years of age with severe haemophilia B // Haemophilia. Haemophilia, 2010. Vol. 16, № 3. P. 460–468.
  33. Инструкция по медицинскому применению лекарственного препарата Иннонафактор®. ЛП 002662. 2021.
  34. Mahlangu J. et al. Emicizumab Prophylaxis in Patients Who Have Hemophilia A without Inhibitors // N. Engl. J. Med. Massachussetts Medical Society, 2018. Vol. 379, № 9. P. 811–822.
  35. Ljung R. et al. Inhibitors in haemophilia A and B: Management of bleeds, inhibitor eradication and strategies for difficult‐to‐treat patients // Eur. J. Haematol. Wiley-Blackwell, 2019. Vol. 102, № 2. P. 111.
  36. Gringeri A. et al. Sequential combined bypassing therapy is safe and effective in the treatment of unresponsive bleeding in adults and children with haemophilia and inhibitors // Haemophilia. Haemophilia, 2011. Vol. 17, № 4. P. 630–635.
  37. Флоринский Д.Б., Жарков П.А. Современные подходы к лечению гемофилии // Вопросы гематологии / онкологии и иммунопатологии в педиатрии. 2020. Vol. 19, № 3. P. 131–138.
  38. Rocino A., Franchini M., Coppola A. Treatment and Prevention of Bleeds in Haemophilia Patients with Inhibitors to Factor VIII/IX // J. Clin. Med. J Clin Med, 2017. Vol. 6, № 4.
  39. Инструкция по медицинскому применению лекарственного препарата Фейба® П N013644/01-180521.
  40. Valentino L.A. The benefits of prophylactic treatment with APCC in patients with haemophilia and high-titre inhibitors: a retrospective case series // Haemophilia. Haemophilia, 2009. Vol. 15, № 3. P. 733–742.
  41. Nakar C., Shapiro A. Hemophilia A with inhibitor: Immune tolerance induction (ITI) in the mirror of time // Transfusion and Apheresis Science. Elsevier Ltd, 2019. Vol. 58, № 5. P. 578–589.
  42. Wight J., Paisley S., Knight C. Immune tolerance induction in patients with haemophilia A with inhibitors: a systematic review // Haemophilia. Haemophilia, 2003. Vol. 9, № 4. P. 436–463.
  43. Holstein K. et al. Immune tolerance induction in the era of emicizumab - still the first choice for patients with haemophilia A and inhibitors? // Haemophilia. Haemophilia, 2022. Vol. 28, № 2. P. 215–222.
  44. Hart D.P. et al. Immune tolerance induction in severe haemophilia A: A UKHCDO inhibitor and paediatric working party consensus update // Haemophilia. Haemophilia, 2021. Vol. 27, № 6. P. 932–937.
  45. Carcao M. et al. The changing face of immune tolerance induction in haemophilia A with the advent of emicizumab // Haemophilia. Wiley-Blackwell, 2019. Vol. 25, № 4. P. 676.
  46. Gualtierotti R. et al. Current and Emerging Approaches for Pain Management in Hemophilic Arthropathy // Pain Ther. Adis, 2022. Vol. 11, № 1. P. 1–15.
  47. Rodriguez-Merchan E.C. Hemophilic Pseudotumors: Diagnosis and Management // Arch. Bone Jt. Surg. Mashhad University of Medical Sciences, 2020. Vol. 8, № 2. P. 121.
  48. Taşer Ö. Treatment of Closed Fractures in Hemophiliac Patients // Orthopedic Surgery in Patients with Hemophilia / ed. Caviglia H.A., Solimeno L.P. Springer, 2008. P. 257–262.
  49. Инструкция по медицинскому применению лекарственного препарата Нувик®. РУ ЛП 003522. 2021.
  50. Lewandowska M. et al. Management of people with haemophilia A undergoing surgery while receiving emicizumab prophylaxis: Real‐world experience from a large comprehensive treatment centre in the US // Haemophilia. Wiley-Blackwell, 2021. Vol. 27, № 1. P. 90.
  51. Спирин М.В. et al. Периферические имплантируемые центральные венозные катетеры для обеспечения длительного сосудистого доступа у больных с геморрагическим синдромом // Гематология и трансфузиология. 2017. Vol. 64, № 4. P. 203–210.
  52. Fonseca A. et al. Central venous access device insertion and perioperative management of patients with severe haemophilia A: A local experience // Blood Coagul. Fibrinolysis. Lippincott Williams and Wilkins, 2016. Vol. 27, № 2. P. 156–159.
  53. Ullman A.J. et al. Complications of central venous access devices: A systematic review // Pediatrics. American Academy of Pediatrics, 2015. Vol. 136, № 5. P. e1331–e1344.
  54. Valentino L.A. et al. Central venous access devices in haemophilia // Haemophilia. Blackwell Publishing Ltd, 2004. Vol. 10, № 2. P. 134–146.
  55. Valentino L.A., Kawji M., Grygotis M. Venous access in the management of hemophilia // Blood Rev. Churchill Livingstone, 2011. Vol. 25, № 1. P. 11–15.
  56. Santagostino E. et al. A prospective clinical trial of implantable central venous access in children with haemophilia // Br. J. Haematol. Br J Haematol, 1998. Vol. 102, № 5. P. 1224–1228.
  57. Ewenstein B.M. et al. Consensus recommendations for use of central venous access devices in haemophilia // Haemophilia. Haemophilia, 2004. Vol. 10, № 5. P. 629–648.
  58. Morado M. et al. Complications of central venous catheters in patients with haemophilia and inhibitors // Haemophilia. Haemophilia, 2001. Vol. 7, № 6. P. 551–556.
  59. Castaman G. et al. Molecular and phenotypic determinants of the response to desmopressin in adult patients with mild hemophilia A // J. Thromb. Haemost. J Thromb Haemost, 2009. Vol. 7, № 11. P. 1824–1831.
  60. Franchini M., Zaffanello M., Lippi G. The use of desmopressin in mild hemophilia A // Blood Coagulation and Fibrinolysis. Blood Coagul Fibrinolysis, 2010. Vol. 21, № 7. P. 615–619.
  61. von Depka M. Managing acute bleeds in the patient with haemophilia and inhibitors: Options, efficacy and safety // Haemophilia, Supplement. Haemophilia, 2005. Vol. 11, № 1. P. 18–23.
  62. Chin X. et al. Desmopressin therapy in children and adults: pharmacological considerations and clinical implications // Eur. J. Clin. Pharmacol. Eur J Clin Pharmacol, 2022. Vol. 78, № 6. P. 907–917.
  63. Liu X. et al. Evolutionary features of thyroid cancer in patients with thyroidectomies from 2008 to 2013 in China // Sci. Rep. Nature Publishing Group, 2016. Vol. 6.

Для продолжения работы требуется Registration
На предыдущую страницу

Предыдущая страница

Следующая страница

На следующую страницу
Список литературы
На предыдущую главу Предыдущая глава
оглавление
Следующая глава На следующую главу